The Cancer Vaccine That Could Save Moderna
Summary
Moderna’s stock plummeted 90% as COVID vaccine sales faded, but a breakthrough melanoma vaccine trial has revived the biotech giant. Partnering with Merck, Moderna’s mRNA therapy showed promise in preventing cancer recurrence, marking a pivotal shift from infectious diseases to oncology. This success validates years of risky investment and positions Moderna as a leading player in personalized cancer treatment, potentially transforming its financial future.
Topics discussed
Moderna's stock crash and surprising cancer vaccine breakthrough
Sponsors: Harvey AI and Indeed Sponsored Jobs
Moderna's origins and early hesitation to target cancer
Internal debate: Realists vs. Dreamers on oncology
A $500k donation kickstarts the cancer vaccine program
Partnership with Merck and the start of clinical trials
COVID-19 pandemic derails cancer research but brings wealth
Post-pandemic struggles and promising Phase 2 results
Phase 3 success and emotional celebration at Moderna
FDA approval hopes and future of mRNA oncology
New show 'My Monday Morning' and episode credits
Listen ad-free on Castria